Three years after it started working with Pfizer, artificial intelligence-powered drug discovery specialist CytoReason has converted the relationship into a lucrative, wide-ranging contract
Neurodegenerative diseases like Parkinson’s and Alzheimer’s affect millions of people worldwide, and their prevalence is only increasing, according to the World Health Organization.
US medical device firm Neurametrix has struck an agreement with N-Strategy Consulting Services (NSCS) to invest in a test for neurological diseases based around typing cadence in the Asia-P
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
